aTyr Pharma Inc (LIFE)
1.57
-0.02
(-1.57%)
USD |
NASDAQ |
Apr 26, 16:00
1.60
+0.03
(+1.91%)
After-Hours: 20:00
aTyr Pharma Total Assets (Quarterly): 120.65M for Dec. 31, 2023
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 120.65M |
September 30, 2023 | 125.07M |
June 30, 2023 | 132.75M |
March 31, 2023 | 136.84M |
December 31, 2022 | 95.79M |
September 30, 2022 | 96.06M |
June 30, 2022 | 96.02M |
March 31, 2022 | 104.78M |
December 31, 2021 | 115.54M |
September 30, 2021 | 123.92M |
June 30, 2021 | 49.00M |
March 31, 2021 | 55.13M |
December 31, 2020 | 38.73M |
September 30, 2020 | 41.64M |
June 30, 2020 | 47.56M |
March 31, 2020 | 54.45M |
December 31, 2019 | 36.19M |
September 30, 2019 | 43.74M |
June 30, 2019 | 48.76M |
Date | Value |
---|---|
March 31, 2019 | 49.92M |
December 31, 2018 | 52.75M |
September 30, 2018 | 59.77M |
June 30, 2018 | 68.31M |
March 31, 2018 | 78.47M |
December 31, 2017 | 89.36M |
September 30, 2017 | 94.49M |
June 30, 2017 | 61.47M |
March 31, 2017 | 65.74M |
December 31, 2016 | 80.52M |
September 30, 2016 | 85.92M |
June 30, 2016 | 100.49M |
March 31, 2016 | 115.12M |
December 31, 2015 | 129.68M |
September 30, 2015 | 141.37M |
June 30, 2015 | 153.08M |
March 31, 2015 | 59.90M |
December 31, 2014 | 20.64M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
36.19M
Minimum
Dec 2019
136.84M
Maximum
Mar 2023
82.24M
Average
95.79M
Median
Dec 2022
Total Assets (Quarterly) Benchmarks
Vaxart Inc | 91.83M |
Allogene Therapeutics Inc | 642.84M |
AIM ImmunoTech Inc | 19.38M |
Protalix BioTherapeutics Inc | 84.43M |
Armata Pharmaceuticals Inc | 98.36M |
Total Assets (Quarterly) Related Metrics
Total Liabilities (Quarterly) | 30.18M |
Shareholders Equity (Quarterly) | 90.66M |